Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 3
1981 3
1982 3
1983 1
1984 5
1985 1
1986 3
1987 1
1988 1
1989 1
1991 1
1993 1
1994 2
1995 1
1997 5
1998 7
1999 5
2000 7
2001 3
2002 7
2003 5
2004 10
2005 7
2006 9
2007 12
2008 13
2009 17
2010 14
2011 13
2012 11
2013 8
2014 12
2015 17
2016 20
2017 10
2018 14
2019 16
2020 12
2021 18
2022 11
2023 17
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

294 results

Results by year

Filters applied: . Clear all
Page 1
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.
Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S; GENTHEP Investigators; Bioulac-Sage P, Letouzé E, Zucman-Rossi J. Nault JC, et al. Gastroenterology. 2017 Mar;152(4):880-894.e6. doi: 10.1053/j.gastro.2016.11.042. Epub 2016 Dec 7. Gastroenterology. 2017. PMID: 27939373 Free article.
Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study.
Louvet A, Labreuche J, Moreno C, Vanlemmens C, Moirand R, Féray C, Dumortier J, Pageaux GP, Bureau C, Chermak F, Duvoux C, Thabut D, Leroy V, Carbonell N, Rolland B, Salamé E, Anty R, Gournay J, Delwaide J, Silvain C, Lucidi V, Lassailly G, Dharancy S, Nguyen-Khac E, Samuel D, Duhamel A, Mathurin P; QuickTrans trial study group. Louvet A, et al. Lancet Gastroenterol Hepatol. 2022 May;7(5):416-425. doi: 10.1016/S2468-1253(21)00430-1. Epub 2022 Feb 23. Lancet Gastroenterol Hepatol. 2022. PMID: 35202597 Free article. Clinical Trial.
The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
Bureau C, Thabut D, Jezequel C, Archambeaud I, D'Alteroche L, Dharancy S, Borentain P, Oberti F, Plessier A, De Ledinghen V, Ganne-Carrié N, Carbonell N, Rousseau V, Sommet A, Péron JM, Vinel JP. Bureau C, et al. Among authors: peron jm. Ann Intern Med. 2021 May;174(5):633-640. doi: 10.7326/M20-0202. Epub 2021 Feb 2. Ann Intern Med. 2021. PMID: 33524293 Clinical Trial.
The pressing need for a global HEV vaccine.
Peron JM, Larrue H, Izopet J, Buti M. Peron JM, et al. J Hepatol. 2023 Sep;79(3):876-880. doi: 10.1016/j.jhep.2023.03.024. Epub 2023 Mar 30. J Hepatol. 2023. PMID: 37003442 Review.
TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis.
Larrue H, D'Amico G, Olivas P, Lv Y, Bucsics T, Rudler M, Sauerbruch T, Hernandez-Gea V, Han G, Reiberger T, Thabut D, Vinel JP, Péron JM, García-Pagán JC, Bureau C. Larrue H, et al. Among authors: peron jm. J Hepatol. 2023 Sep;79(3):692-703. doi: 10.1016/j.jhep.2023.04.028. Epub 2023 May 2. J Hepatol. 2023. PMID: 37141993
Hepatitis E virus.
Abravanel F, Lhomme S, Dubois M, Peron JM, Alric L, Kamar N, Izopet J. Abravanel F, et al. Among authors: peron jm. Med Mal Infect. 2013 Jul;43(7):263-70. doi: 10.1016/j.medmal.2013.03.005. Epub 2013 Apr 20. Med Mal Infect. 2013. PMID: 23608595 Review.
Hepatitis E, what's the real issue?
Larrue H, Abravanel F, Péron JM. Larrue H, et al. Among authors: peron jm. Liver Int. 2020 Feb;40 Suppl 1:43-47. doi: 10.1111/liv.14351. Liver Int. 2020. PMID: 32077607 Review.
294 results